Cargando…

Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients

BACKGROUND: Immunotherapy plus tyrosine kinase inhibitor (IO-TKI) has become the first-line management for metastatic renal cell carcinoma (RCC), despite the absence of biomarkers. Recently, pyrroline-5-carboxylate reductase 1 (PYCR1) and proline metabolism have been reported regulatory roles in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Xianglai, Wang, Ying, Hu, Xinyu, Zhu, Yanjun, Wang, Jiajun, Guo, Jianming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404727/ https://www.ncbi.nlm.nih.gov/pubmed/37517099 http://dx.doi.org/10.1016/j.neo.2023.100919

Ejemplares similares

Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression
por: Xu, Xianglai, et al.
Publicado: (2023)

HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma
por: Xu, Xianglai, et al.
Publicado: (2023)

PYCR1 is Associated with Papillary Renal Cell Carcinoma Progression
por: Wang, Qiu-Li, et al.
Publicado: (2019)

The clinical significance of PYCR1 expression in renal cell carcinoma
por: Weijin, Fu, et al.
Publicado: (2019)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
por: Yang, Yuanquan, et al.
Publicado: (2022)

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
por: Xia, Yu, et al.
Publicado: (2017)

Targeting PYCR2 inhibits intraperitoneal metastatic tumors of mouse colorectal cancer in a proline‐independent approach
por: Zhang, Qi, et al.
Publicado: (2022)

PYCR1 and PYCR2 Interact and Collaborate with RRM2B to Protect Cells from Overt Oxidative Stress
por: Kuo, Mei-Ling, et al.
Publicado: (2016)

Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
por: Rassy, Elie, et al.
Publicado: (2020)

Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Xi, Wei, et al.
Publicado: (2021)

Increased PYCR1 mRNA predicts poor prognosis in kidney adenocarcinoma: A study based on TCGA database
por: Zhang, Tianyi, et al.
Publicado: (2021)

Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma
por: Xu, Yanzhen, et al.
Publicado: (2021)

PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
por: Wang, Huanyu, et al.
Publicado: (2022)

Checkpoint molecule PD-1-assisted CD8(+) T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Yao, Jiaxi, et al.
Publicado: (2018)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

PYCR2 Mutation Causing Hypomyelination and Microcephaly in an Indian Child
por: Srivastava, Preeti, et al.
Publicado: (2021)

MicroRNA hsa-miR-150-5p inhibits nasopharyngeal carcinogenesis by suppressing PYCR1 (pyrroline-5-carboxylate reductase 1)
por: Li, Zhiqun, et al.
Publicado: (2021)

Survival and clinicopathological significance of PYCR1 expression in cancer: A meta-analysis
por: Li, Yue, et al.
Publicado: (2022)

Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
por: Laccetti, Andrew L., et al.
Publicado: (2021)

Fasting plus tyrosine kinase inhibitors in cancer
por: Caffa, Irene, et al.
Publicado: (2015)

Low CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma
por: Xiong, Ying, et al.
Publicado: (2016)

PYCR1 interference inhibits cell growth and survival via c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathway in hepatocellular cancer
por: Zhuang, Juhua, et al.
Publicado: (2019)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

IRF5 is associated with adverse postoperative prognosis of patients with non-metastatic clear cell renal cell carcinoma
por: Bai, Qi, et al.
Publicado: (2017)

Tyrosine kinase inhibitors reprogramming immunity in renal cell carcinoma: rethinking cancer immunotherapy
por: Aparicio, L. M. A., et al.
Publicado: (2017)

In crystallo screening for proline analog inhibitors of the proline cycle enzyme PYCR1
por: Christensen, Emily M., et al.
Publicado: (2021)

Metabolomic and transcriptomic studies of improvements in myocardial infarction due to Pycr1 deletion
por: Xue, Zhimin, et al.
Publicado: (2022)

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
por: Wang, Kun, et al.
Publicado: (2023)

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

Exploration of Prognostic Biomarkers of Muscle-Invasive Bladder Cancer (MIBC) by Bioinformatics
por: Xu, Xianglai, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

SIRT3 regulates cancer cell proliferation through deacetylation of PYCR1 in proline metabolism()
por: Chen, Shuaiyi, et al.
Publicado: (2019)

Zebrafish Carrying pycr1 Gene Deficiency Display Aging and Multiple Behavioral Abnormalities
por: Liang, Sung-Tzu, et al.
Publicado: (2019)

Mutation in PYCR2 gene and hypomyelinating leukodystrophy in children: a case report study
por: Hosseini, Seyed Ahmad, et al.
Publicado: (2023)

Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis
por: He, Ying, et al.
Publicado: (2021)

High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma
por: WEI, CAN, et al.
Publicado: (2013)

Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy
por: Zhao, Xiashuang, et al.
Publicado: (2023)

ALKBH5-PYCR2 Positive Feedback Loop Promotes Proneural-Mesenchymal Transition Via Proline Synthesis In GBM
por: Li, Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lflodrmcs3ui45ov01r69bvq21